Oral Minoxidil

Why there is no syringe

There is no syringe — minoxidil tablets are swallowed — but the more useful thing to say in this field is what the absence of one does not imply. A tablet being easy to take is not the same as a tablet being low-risk, and this is the only compound in the hair set carrying a boxed warning. The label reserves it for hypertensive patients who have already failed a diuretic plus two other antihypertensive agents, requires it to be given alongside a beta-blocker and a loop diuretic, and warns that it “can cause pericardial effusion, occasionally progressing to tamponade”. The low-dose regimens used for hair loss are not on this label in any form, so nothing here converts a 2.5 mg or 10 mg tablet into a hair-loss dose.

Administration

1. 1

   Read the boxed warning before anything else

   It is the first thing on the label and it is short: “Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents.” The warning continues that minoxidil “must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload”, and “must also usually be given with a diuretic”.

2. 2

   Know that the label itself says hair growth is not an approved use

   This is not an inference from the absence of an indication. The label carries a numbered section under PRECAUTIONS headed “Unapproved Use”, which states: “Use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication. While clinical trials with ROGAINE® Topical Solution 2% demonstrated that formulation and dosage were safe and effective, the effects of extemporaneous formulations and dosages have not been shown to be safe or effective.” It adds that extemporaneous topical preparations made from the tablets “should be considered to share in the full range of CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS listed in this insert”.

3. 3

   Understand what the approved indication actually is

   “Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.” That is a last-line indication, and the word in it is “only”.

4. 4

   Do not take it without the companion drugs the label requires

   The label does not treat the diuretic and the beta-blocker as options. “Minoxidil tablets must usually be administered concomitantly with a diuretic adequate to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required,” and “the increase in rate and the occurrence of angina generally can be prevented by the concomitant administration of a beta-adrenergic blocking drug or other sympathetic nervous system suppressant.” Without a diuretic, the label states, “retention of several hundred milli-equivalents of salt and corresponding volumes of water can occur within a few days”.

5. 5

   Titrate no faster than the label allows, and only under supervision

   “Dosage must be titrated carefully according to individual response. Intervals between dosage adjustments normally should be at least 3 days since the full response to a given dose is not obtained for at least that amount of time.” The label also requires that patients with malignant hypertension, or those already on guanethidine, begin treatment in hospital.

6. 6

   Weigh yourself and know the fluid-overload symptoms

   The label’s Information for Patient section states: “The patient should be fully aware of the importance of continuing all of his antihypertensive medications and of the nature of symptoms that would suggest fluid overload.” It directs that body weight be monitored closely, and that a gain of more than five pounds from salt and water retention should change the diuretic to furosemide or raise the furosemide dose.

Storage

• —Store at controlled room temperature 20–25 °C (68–77 °F) [see USP] — quoted from the HOW SUPPLIED section of the minoxidil tablets label.
• —Supplied as 2.5 mg and 10 mg white, round, bisected tablets. “FOR YOUR PROTECTION: Do not use if blister is torn or broken.”
• —Keep out of reach of children. The tablets are uncoated and bisected, so a loose tablet is not distinguishable by sight from any other small white tablet.

Monitoring

Frequently asked questions

Is oral minoxidil more effective than the topical solution?

Not by the evidence we can find, and the trade is the other way round. A 2025 meta-analysis of four randomised trials in 279 patients (Int J Dermatol 2025;64(3):479-484) concluded that "oral minoxidil and minoxidil topical solution have similar efficacy and safety", with no difference in hair density or hair diameter — but hypertrichosis, hair growing where it is not wanted, was twice as common on the oral route (relative risk 2.01, 95% confidence interval 1.18 to 3.41). Note what that study is and is not: it compares two fixed off-label regimens at the doses those trials happened to use. It publishes no conversion between an oral dose and a topical strength, and we could find none anywhere, which is why this site has no oral-to-topical calculator and will not be adding one.

Is oral minoxidil approved for hair loss?

No, and the label says so in its own words rather than leaving it to be inferred. Under PRECAUTIONS it carries a section headed “Unapproved Use”: “Use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication.” The only approved indication is hypertension “that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs”. Low-dose oral minoxidil for androgenetic alopecia is a prescribing pattern, not a labelled use, and this page states no dose for it.

What is the boxed warning on minoxidil tablets?

Quoted in full: “Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents.” The warning goes on to require close supervision, a concomitant beta-blocker to prevent tachycardia and increased myocardial workload, and usually a loop diuretic to prevent serious fluid accumulation.

How common is pericardial effusion on minoxidil tablets?

The label gives a figure for the population it was studied in, and it is worth reading carefully: “Pericardial effusion, occasionally with tamponade, has been observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function.” Those patients were taking antihypertensive doses — 10 to 40 mg a day — for severe hypertension, frequently with renal impairment. That figure is not a prediction for a healthy man taking a fraction of that dose for hair, and no labelled figure exists for the low-dose hair-loss use because it is not a labelled use. Naming the risk without a rate is the honest position here.

What dose does the label state?

For blood pressure only: “The recommended initial dosage of minoxidil tablets is 5 mg given as a single daily dose. Daily dosage can be increased to 10 mg, 20 mg and then to 40 mg in single or divided doses if required for optimum blood pressure control. The effective dosage range is usually 10 mg to 40 mg per day. The maximum recommended dosage is 100 mg per day.” Tablets are supplied at 2.5 mg and 10 mg. Nothing in that schedule is a hair-loss dose, and this page does not translate it into one.

Is Loniten still available?

Not as a brand. LONITEN (NDA 018154, Pfizer) is listed in Drugs@FDA as discontinued in both the 2.5 mg and 10 mg strengths, with a Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. Minoxidil tablets remain available as prescription generics — the label quoted here is an ANDA product (ANDA 071826 and ANDA 071839) — and they carry the same boxed warning.

How is this different from the minoxidil in Rogaine?

Same molecule, opposite regulatory positions. The topical 2% and 5% products are FDA-approved over-the-counter treatments for male pattern hair loss at the vertex. The tablets are prescription-only, approved for last-line hypertension, and carry a boxed warning; their own label states that using them to promote hair growth is not an approved indication, and warns that preparations improvised from the tablets “should be considered to share in the full range of CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS listed in this insert”.

Sources

1. [1]FDA label — Minoxidil Tablets, USP, American Health Packaging (DailyMed SPL 0b4fc036-9497-442b-b629-c4b386932789; marketing category ANDA, Drugs@FDA ANDA 071826 and ANDA 071839). Source of the boxed warning, the hypertension-only indication, the “Unapproved Use” section on hair growth, the 5–100 mg antihypertensive dosing, the 3% pericardial effusion figure and the monitoring intervals
2. [2]Drugs@FDA: FDA-Approved Drugs — used to confirm that LONITEN (NDA 018154, Pfizer) is discontinued in both strengths with a Federal Register determination that it was not withdrawn for safety or effectiveness reasons, and that the marketed minoxidil tablets are prescription ANDA products
3. [3]FDA label — MEN’S ROGAINE EXTRA STRENGTH UNSCENTED (minoxidil) 5% topical solution, Kenvue Brands LLC (Drugs@FDA NDA 020834). The approved topical route the tablet label itself points at when it says hair-growth use of the tablets is unapproved

Related

• Topical minoxidil — the approved route
• Finasteride — the labelled hair-loss 5-ARI
• Norwood scale — stage your hair loss
• Compare online hair loss providers
• Hair restoration: what the evidence supports